Date lodged: 30 June 2016
To ask the Scottish Government what its position is on the use of autologous haematopoietic stem cell transplantation in the treatment of (a) relapsing remitting and (b) secondary progressive multiple sclerosis.
Answered by: Aileen Campbell 12 July 2016
The Scottish Government understands that Autologous Haematopoietic Stem Cell Transplant (HSCT) is currently considered to be effective for people with highly active relapsing remitting multiple sclerosis (MS) who have already trialled other highly effective drugs or forms of immunomodulatory treatment. Unfortunately, many of the people requesting this treatment have progressive forms of MS, for which it is not presently shown to help.
HSCT is not widely available anywhere on the NHS for people with MS at present, but is currently being trialled across the UK. Clinical trials and other emerging treatments are continually monitored to see if there are any potential benefits to patients in Scotland, and we would expect the NHS to act appropriately regarding HSCT once the evidence is considered and a clinical consensus is reached.